TY - JOUR
T1 - Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
AU - Yanik, Gregory
AU - Hellerstedt, Beth
AU - Custer, Joseph
AU - Hutchinson, Raymond
AU - Kwon, Deborah
AU - Ferrara, James L.M.
AU - Uberti, Joseph
AU - Cooke, Kenneth R.
PY - 2002
Y1 - 2002
N2 - Acute pulmonary dysfunction remains a frequent and severe complication of hematopoietic stem cell transplantation (SCT). Almost half of the pulmonary insults that occur in this setting are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). In this series of 3 patients, etanercept (Enbrel; Immunex, Seattle, WA), a soluble, dimeric tumor necrosis factor α-binding protein, was administered to 3 consecutive pediatric allogeneic BMT recipients with IPS. The administration of etanercept, in combination with standard immunosuppressive therapy, was well tolerated and associated with significant improvements in pulmonary dysfunction within the first week of theraphy. These data suggest that etanercept may represent a safe, non-cross-reactive, therapeutic option for patients with IPS and that clinical trials studying etanercept for this indication are warranted.
AB - Acute pulmonary dysfunction remains a frequent and severe complication of hematopoietic stem cell transplantation (SCT). Almost half of the pulmonary insults that occur in this setting are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). In this series of 3 patients, etanercept (Enbrel; Immunex, Seattle, WA), a soluble, dimeric tumor necrosis factor α-binding protein, was administered to 3 consecutive pediatric allogeneic BMT recipients with IPS. The administration of etanercept, in combination with standard immunosuppressive therapy, was well tolerated and associated with significant improvements in pulmonary dysfunction within the first week of theraphy. These data suggest that etanercept may represent a safe, non-cross-reactive, therapeutic option for patients with IPS and that clinical trials studying etanercept for this indication are warranted.
KW - Allogeneic BMT
KW - Pulmonary dysfunction
KW - Tumor necrosis factor α (TNFα)
UR - http://www.scopus.com/inward/record.url?scp=0036051448&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036051448&partnerID=8YFLogxK
U2 - 10.1053/bbmt.2002.v8.pm12171486
DO - 10.1053/bbmt.2002.v8.pm12171486
M3 - Article
C2 - 12171486
AN - SCOPUS:0036051448
SN - 1083-8791
VL - 8
SP - 395
EP - 400
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 7
ER -